Home Objective Mobility Exam (HOME) for Balance and Gait Disorders in Parkinson's

主页 针对帕金森病平衡和步态障碍的目标行动能力检查 (HOME)

基本信息

  • 批准号:
    8519026
  • 负责人:
  • 金额:
    $ 34.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-06-01 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Although balance and gait disorders are one of the most common and devastating chronic medical problems of older people, especially those with chronic neurological diseases, clinicians or clinical researchers do not measure balance and gait frequently, accurately, or sensitively. Our long-term goal is to develop and commercialize a unique system called the Home Objective Mobility Exam (HOME) to allow patients to measure their own balance and gait at home. If physicians and physical therapists could obtain frequent, accurate, self-administered measures of balance and gait characteristics, then they will be able to earlier predict fall risk and changes in mobility. This will also enable them to quickly improve interventions in order to prevent mobility disability. The objective of this application is to deveop a novel method to allow patients to quantify their own standing balance, gait and turning with a quick, simple, and extremely easy to use system. The specifc aims are: Aim I. To develop a new version of the Opal movement monitor for home use. The objective of this aim is to transform the Opal sensors from a computer-based clinician/researcher-controlled system to a nonprofessional/patient-controlled system of movement monitoring. Aim II. To determine the feasibility, validity and reliability of having people with Parkinson's disease test their own balance and gait at home. We hypothesize that balance and gait, measured by patients in their homes, will be valid and reliable compared with measures administered by research assistants and with clinical scales and show very good test-retest reliability. We will initially develop HOME for patients with Parkinson's disease because they have more falls than any other neurological disorder, but we are confident that this tool will be useful for patients any form of mobility disability, such as multiple sclerosis, stroke, head injury, developmental disorders, multisensory deficits, frail elderly, etc. Based on results of this proposal, our Phase II application will thentest the ability of the HOME to more quickly detect changes in balance and gait following a change in medication or physical therapy, compared to usual care, in preparation for FDA approval and widespread marketing.
描述(申请人提供):虽然平衡和步态障碍是老年人,特别是患有慢性神经系统疾病的人最常见和最具破坏性的慢性医学问题之一,但临床医生或临床研究人员并不经常、准确或敏感地测量平衡和步态。我们的长期目标是开发一种独特的系统并将其商业化,该系统名为Home客观移动性检查(HOME),允许患者在家中测量自己的平衡和步态。如果医生和理疗师能够获得频繁、准确、自我管理的平衡和步态特征测量,那么他们就能够更早地预测跌倒的风险和活动能力的变化。这也将使他们能够迅速提高 干预措施,以预防行动不便。这项应用的目的是开发一种新的方法,使患者能够用一个快速、简单和极易使用的系统来量化他们自己的站立平衡、步态和转身。具体目标是:目标一、开发家用新型蛋白石运动监测器。这一目标的目的是将Opal传感器从基于计算机的临床医生/研究人员控制的系统转变为非专业/患者控制的运动监测系统。目的II.确定帕金森病患者在家中测试自身平衡和步态的可行性、效度和可靠性。我们假设,由患者在家中测量的平衡和步态,与研究助理和临床量表的测量相比,将是有效和可靠的,并显示出非常好的重测可靠性。我们将初步开发家居 对于帕金森氏症患者,因为他们比其他任何神经疾病患者有更多的跌倒,但我们有信心这一工具将适用于任何形式的行动障碍,如多发性硬化症,中风,头部损伤,发育障碍,多感官缺陷,虚弱的老年人等。基于这项建议的结果,我们的第二阶段应用将测试家庭在药物或物理治疗改变后更快检测平衡和步态变化的能力,与通常的护理相比,为FDA的批准和广泛的营销做准备。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mahmoud El-Gohary其他文献

Mahmoud El-Gohary的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mahmoud El-Gohary', 18)}}的其他基金

Home biofeedback (VibroGait) for people with impaired somatosensation
针对体感受损人士的家庭生物反馈 (VibroGait)
  • 批准号:
    10011639
  • 财政年份:
    2020
  • 资助金额:
    $ 34.98万
  • 项目类别:
Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease
移动生活:监测神经系统疾病患者日常生活中的移动能力
  • 批准号:
    9202863
  • 财政年份:
    2016
  • 资助金额:
    $ 34.98万
  • 项目类别:
Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease
移动生活:监测神经系统疾病患者日常生活中的移动能力
  • 批准号:
    9523322
  • 财政年份:
    2016
  • 资助金额:
    $ 34.98万
  • 项目类别:
Monitoring Balance and Gait Disorders in Parkinson???s Disease with the Home Obje
使用 Home Obje 监测帕金森病的平衡和步态障碍
  • 批准号:
    8665857
  • 财政年份:
    2013
  • 资助金额:
    $ 34.98万
  • 项目类别:
A Short Instrumented Test of Mobility for Neurological Disorders
神经系统疾病流动性的简短仪器测试
  • 批准号:
    8705232
  • 财政年份:
    2012
  • 资助金额:
    $ 34.98万
  • 项目类别:

相似海外基金

Evaluating the association between mean arterial blood pressure through the first 24 hours after cardiac surgery and postoperative acute kidney injury
评估心脏手术后 24 小时内的平均动脉血压与术后急性肾损伤之间的关联
  • 批准号:
    10742695
  • 财政年份:
    2023
  • 资助金额:
    $ 34.98万
  • 项目类别:
Cardiac biomarkers, intensive blood pressure treatment and risk of adverse cardiovascular outcomes in type 2 diabetes, a secondary analysis of the ACCORD BP
心脏生物标志物、强化血压治疗和 2 型糖尿病不良心血管结局的风险,ACCORD BP 的二次分析
  • 批准号:
    10728787
  • 财政年份:
    2023
  • 资助金额:
    $ 34.98万
  • 项目类别:
The cardiac-sympathetic contribution to blood pressure regulation
心脏交感神经对血压调节的贡献
  • 批准号:
    RGPIN-2020-06240
  • 财政年份:
    2022
  • 资助金额:
    $ 34.98万
  • 项目类别:
    Discovery Grants Program - Individual
Characteristics of skin color in healthy subjects and patients with cardiac or pulmonary diseases: Relationship between blood pressure or hemoglobin and skin color
健康受试者和心肺疾病患者的肤色特征:血压或血红蛋白与肤色的关系
  • 批准号:
    22K12925
  • 财政年份:
    2022
  • 资助金额:
    $ 34.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Endovascular blood pressure targeting in cardiac arrest, a translational research study
心脏骤停中的血管内血压目标,一项转化研究
  • 批准号:
    10693924
  • 财政年份:
    2022
  • 资助金额:
    $ 34.98万
  • 项目类别:
The cardiac-sympathetic contribution to blood pressure regulation
心脏交感神经对血压调节的贡献
  • 批准号:
    RGPIN-2020-06240
  • 财政年份:
    2021
  • 资助金额:
    $ 34.98万
  • 项目类别:
    Discovery Grants Program - Individual
The cardiac-sympathetic contribution to blood pressure regulation
心脏交感神经对血压调节的贡献
  • 批准号:
    DGECR-2020-00128
  • 财政年份:
    2020
  • 资助金额:
    $ 34.98万
  • 项目类别:
    Discovery Launch Supplement
The cardiac-sympathetic contribution to blood pressure regulation
心脏交感神经对血压调节的贡献
  • 批准号:
    RGPIN-2020-06240
  • 财政年份:
    2020
  • 资助金额:
    $ 34.98万
  • 项目类别:
    Discovery Grants Program - Individual
Novel Protein Kinase GI Substrates in Cardiac Remodeling and Blood Pressure Control
心脏重塑和血压控制中的新型蛋白激酶 GI 底物
  • 批准号:
    9899289
  • 财政年份:
    2016
  • 资助金额:
    $ 34.98万
  • 项目类别:
CLOSED-LOOP BLOOD PRESSURE CONTROL BY NEURAL STIMULATION FOR CARDIAC CARE ENVIRONMENT
通过神经刺激控制心脏护理环境的闭环血压
  • 批准号:
    9099079
  • 财政年份:
    2016
  • 资助金额:
    $ 34.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了